# Biotroy Therapeutics

Source: https://onco.cc/companies/biotroy-therapeutics/  
OnCo record `biotroy-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Biotroy Therapeutics is a Shanghai company developing antibodies against newly discovered immune checkpoints, the brakes that tumours use to switch off the immune system. Its first antibody, BT02, is in early trials in melanoma, lung cancer and blood cancers.

## Summary

Shanghai Biotroy Biotechnology Co., Ltd. (BioTroy), at Zhangheng Road, Pudong, Shanghai, was founded in 2019, according to the company, by Dr Jie Xu, whose laboratory reported new immune checkpoints including CD3L1 (TPRIPL1, Cell 2024) and galectin-8 as an LILRB4 ligand. The company develops first-in-class monoclonal antibodies against original tumour immunology targets; its pipeline lists BT01 and BT02 for solid tumours, BT03 and an undisclosed BT04. It reports a first US IND clearance in 2023 and a first China IND clearance in 2024. BT02, an intravenous monoclonal antibody, is in three ClinicalTrials.gov studies posted in August 2025: a phase 1b study in advanced melanoma with Peking University Cancer Hospital (NCT07107178), a phase 1 study in advanced lung cancer (NCT07110363) and a phase 1/2 study in relapsed or refractory haematological cancers (NCT07107204). Investors named on its site are Kaifeng Venture, Hongke Capital, Xiantong Capital and the Shanghai Biomedical Fund; the company reports an angel round of tens of millions of yuan and a Pre-A round of over 100 million yuan. Its first registered cancer trial, NCT07107178, was posted on ClinicalTrials.gov in August 2025.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: BioTroy; Shanghai Biotroy Biotechnology
- HQ: Shanghai
- Type: biotech
- Website: http://www.biotroy.cn/

## Notes

- Read on 29 October 2026: biotroy.cn home, about (timeline), pipeline, investors and contact pages, in Chinese. The https version of the site returned 403; the http version was read.
- The company does not state BT02's molecular target on the pages read; it is not inferred here. Years and exact amounts of the angel and Pre-A rounds are not clear from the timeline, so no funding rows are listed.
- Trial facts from ClinicalTrials.gov records NCT07107178, NCT07110363 and NCT07107204, read on 29 October 2026.

## Sources

- Official website: http://www.biotroy.cn/
- ClinicalTrials.gov: phase 1b trial of BT02 in advanced melanoma (NCT07107178): https://clinicaltrials.gov/study/NCT07107178
- ClinicalTrials.gov: phase 1 trial of BT02 in advanced lung cancer (NCT07110363): https://clinicaltrials.gov/study/NCT07110363
- ClinicalTrials.gov: phase 1/2 trial of BT02 in haematological cancers (NCT07107204): https://clinicaltrials.gov/study/NCT07107204

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)

---
JSON: https://onco.cc/api/v1/entities/biotroy-therapeutics.json